Advisory Research’s AnaptysBio ANAB Stock Holding History

Advisory Research’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-14,890	Closed	-$1.5M	–	372
2017 Q4	$1.5M	Buy	+14,890	New	+$1.1M	0.02%	244

Other funds holding ANAB

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Advisory Research's ANAB Position: Q1 2018 in Review

Advisory Research sold out of AnaptysBio (ANAB) in Q1 2018, closing a stake of 14,890 shares — an estimated $1.5M sold.

Advisory Research first reported a position in ANAB in Q4 2017 and held it in 1 quarter. The position peaked at $1.5M in Q4 2017. 134 funds tracked by Wall St. Rank hold ANAB as of Q1 2018.

Advisory Research reported no remaining AnaptysBio position as of Q1 2018 after selling out during the quarter.
Advisory Research sold 14,890 AnaptysBio shares in Q1 2018, an estimated $1.5M.
Advisory Research first reported a position in AnaptysBio in Q4 2017 and held it in 1 quarter.
Advisory Research's AnaptysBio position peaked at $1.5M in Q4 2017.
134 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2018.

Based on Advisory Research's 13F filing for Q1 2018, filed 15 May 2018.